z-logo
Premium
Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion
Author(s) -
Cho KyungOk,
La Hyen O.,
Cho YoungJin,
Sung KiWug,
Kim Seong Y.
Publication year - 2005
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.20727
Subject(s) - minocycline , cerebral hypoperfusion , white matter , perfusion , medicine , pharmacology , neuroscience , anesthesia , cardiology , antibiotics , psychology , biology , magnetic resonance imaging , microbiology and biotechnology , radiology
Abstract White matter lesions are thought to result from chronic cerebral ischemia and constitute a core pathology of subcortical vascular dementia. This rarefaction has been known to be associated with microglial activation. We investigated whether minocycline, a microglial inhibitor, attenuates the white matter damage induced by chronic cerebral hypoperfusion that is used as a model of vascular dementia. Male Wistar rats were subjected to bilateral, permanent occlusion of the common carotid arteries (BCCAO) to induce chronic cerebral hypoperfusion. Minocycline or saline was injected daily for 2 weeks after BCCAO. In the corpus callosum and the optic tract, white matter damage observed with Klüver‐Barrera staining was significantly attenuated in the minocycline‐treated group compared to saline‐treated controls. In control rats, immunoreactivities of major basic protein (MBP), Ox‐42 as a microglial marker, and matrix metalloproteinase (MMP)‐2 were increased in the corpus callosum. Minocycline significantly reduced these changes. Co‐expression of Ox‐42 and MMP‐2 was confirmed by double immunofluorescence histochemistry. Our results suggest that chronic treatment with minocycline could be protective against at least some ischemic white matter damage, and its mechanism may be related to suppressing microglial activation. © 2005 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here